Last but not least, IL-1 receptor antagonists blocking IL1RAP, already FDA-approved for the treatment of several inflammatory disorders, could also potentially be used to target CML-LSCs (29). This evidence concerns the gene IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive.